Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

Stock futures dipped on Thursday as investors weighed President Trump’s 90-day tariff reprieve for select countries, which ...

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

Fintel reports that on April 10, 2025, Mizuho initiated coverage of DexCom (NasdaqGS:DXCM) with a Outperform recommendation. Analyst Price Forecast Suggests 57.82% Upside As of April 1, 2025, the ...

DexCom (DXCM) announced the FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for people over the age of 18 with ...

The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system ...

DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...

Notable gainers among liquid option names this morning include DexCom (DXCM) $71.65 +4.81, Consolidated Edison (ED) $108.50 +2.73, SBA ...

DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...

DexCom Inc. closed 52.68% below its 52-week high of $141.25, which the company reached on April 11th.

The San Diego-based medical device company stated that the Dexcom G7 15 Day has an overall Mean Absolute Relative Difference (MARD) of 8.0%, showcasing its precision in glucose level readings. The ...

Dexcom advanced the launch of Stelo, its over-the-counter product for non-insulin type 2 diabetes, pre-diabetes, and ...